Study S000335

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07163624
Acronym: T2DM
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 211
Start: 2025-03-22
Primary completion: 2025-11-21
Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:UBT251 Injection 2.0 mg and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 6.0 mg and UBT251 Injection Placebo; DRUG:Semaglutide Injection (Ozempic®)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:CTR20250029

Registered primary outcomes

Change From Baseline in HbA1c at Week 24 [Baseline to week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.